Study authors performed a post hoc pooled analysis of data from 10 trials to assess the safety and efficacy of umeclidinium/vilanterol in elderly symptomatic patients with COPD.

Researchers found that umeclidinium-vilanterol was associated with a lower risk for a first moderate or severe COPD exacerbation vs glycopyrrolate-formoterol. HealthDay News — Umeclidinium-vilanterol ...

Patients who received fluticasone furoate-vilanterol had a 9% lower risk for a first moderate or severe COPD exacerbation than those who received budesonide-formoterol (hazard ratio [HR], 0.91; 95% CI ...

The US Food and Drug Administration (FDA) today approved umeclidinium and vilanterol powder for inhalation (Anoro Ellipta, GlaxoSmithKline (GSK)/Theravance). The drug is the first combo bronchodilator ...

Treatment with once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) triple therapy appears to be more efficacious in reducing ...

Fluticasone furoate/vilanterol (FF/VI) improved FEV1 but did not improve morning peak expiratory flow in pediatric patients with uncontrolled asthma. Among pediatric patients with uncontrolled asthma, ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

Utility of circulating tumor DNA in patients with resectable pancreatic cancer using a patient-specific panel: ARTEMIS-PC study. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal ...

Please provide your email address to receive an email when new articles are posted on . Risk for first moderate/severe COPD exacerbation was lower among dry powder vs. metered-dose or soft mist ...